Senescence signature in skin biopsies from systemic sclerosis patients treated with senolytic therapy: potential predictor of clinical response?
Abstract
Accumulation of senescent cells has been implicated in the pathogenesis of organ fibrosis and might be therapeutically targeted using senolytic agents. A recent first-in-human open-label trial of senolytic therapy using dasatinib plus quercetin (DQ) in idiopathic pulmonary fibrosis (IPF) revealed that functional clinical improvement was associated with reduced levels of circulating proteins, microRNAs, and cytokines related to senescence-associated secretory phenotype (SASP) (1). This article is protected by copyright. All rights reserved.
Read the paper
Related studies
- Quercetin Influences Quorum Sensing in Food Borne Bacteria: In-Vitro and In-Silico Evidence
- Phenolic-protein interactions: insight from in-silico analyses – a review
- In Silico Discovery of Candidate Drugs against Covid-19
- Neuropharmacological Effects of Quercetin: A Literature-Based Review
- In vitro and in silico anti-dengue activity of compounds obtained from Psidium guajava through bioprospecting
- Effect of Quercetin Rich Onion Extracts on Bacterial Quorum Sensing
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.